ArticleFrontiers in neuroscience2019
The Chemogenetic Receptor Ligand Clozapine N-Oxide Induces
Article in Frontiers in neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Off-target effects of DREADD ligands revealed by an anesthesia emergence paradigm in mice.Cell reports methods · 2026Article
- Contamination of Engram Coactivity Networks During Forgetting.bioRxiv : the preprint server for biology · 2026Article
- Article
- Clozapine N-oxide, compound 21, and JHU37160 do not influence effortful reward-seeking behavior in mice.Psychopharmacology · 2024Article
- Comparison of three DREADD agonists acting on Gq-DREADDs in the ventral tegmental area to alter locomotor activity in tyrosine hydroxylase:Cre male and female rats.Behavioural brain research · 2023Article
- Amygdalo-nigral circuit mediates stress-induced vulnerability to the parkinsonian toxin MPTP.CNS neuroscience & therapeutics · 2023Article
- Bidirectional Modulation of Nociception by GlyT2eNeuro · 2023Article
- Chemogenetic manipulation of astrocyte activity at the synapse- a gateway to manage brain disease.Frontiers in cell and developmental biology · 2023Review
- Deschloroclozapine exhibits an exquisite agonistic effect at lower concentration compared to clozapine-N-oxide in hM3Dq expressing chemogenetically modified rats.Frontiers in neuroscience · 2023Article
- A pilot study of cerebral metabolism and serotonin 5-HTFrontiers in pharmacology · 2023Article
- The use of chemogenetic actuator ligands in nonhuman primate DREADDs-fMRI.Current research in neurobiology · 2023Article
- Validation of DREADD agonists and administration route in a murine model of sleep enhancement.Journal of neuroscience methods · 2022Article
- Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia.Schizophrenia (Heidelberg, Germany) · 2022Article
- Chemogenetics as a neuromodulatory approach to treating neuropsychiatric diseases and disorders.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Dorsal striatal dopamine induces fronto-cortical hypoactivity and attenuates anxiety and compulsive behaviors in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Desorption Electrospray Ionization Mass Spectrometry Imaging of Cimbi-36, a 5-HTMolecular imaging and biology · 2021Article
- Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia.Schizophrenia bulletin · 2021Article
- Suppressing Anterior Cingulate Cortex Modulates Default Mode Network and Behavior in Awake Rats.Cerebral cortex (New York, N.Y. : 1991) · 2021Article
- Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study.Therapeutic advances in psychopharmacology · 2021Article
- A Feasibility Study to Investigate Chemogenetic Modulation of the Locus Coeruleus by Means of Single Unit Activity.Frontiers in neuroscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemogenetic studies with the ligand clozapine N-oxide (CNO) are predicated upon the assumption that CNO is devoid of actions at natural neuroreceptors. However, recent evidence shows that CNO may be converted back to clozapine (CLZ)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.